Detecting earliest population changes of Covid activity with wearable devices

Scripps Research Institute

LA JOLLA, CA—Today, viral illnesses like COVID-19 are tracked using multiple different methods, including lab data, health care visits and wastewater surveillance. According to new data conducted by scientists at the Scripps Research Translational Institute, this arsenal can be expanded to include wearable technologies like fitness devices and smartwatches—which are showing promise in identifying early population changes in COVID-19 activity.

This data comes from the DETECT study: a cross-collaborative effort launched at the onset of the COVID-19 pandemic that uses a mobile app to collect sensor and self-reported information from thousands of study participants across the nation. In addition to the sensor data gathered from a smartwatch, participants can provide details on their test results, vaccinations, symptoms and other demographic information.

In a study published on September 22 in Lancet Digital Health, the scientists found that sensor data significantly improved the seven-day average predictions for COVID-19 infection. This information can provide an earlier signal than traditional surveillance, as it can identify alterations in a person’s data—potentially even before the participant notices their symptoms. With this promising data in hand, this method of tracking could be expanded to monitor additional infectious disease threats well.

“Wearable technologies give us another valuable piece to the COVID-19 tracking puzzle,” says co-senior author Eric Topol, MD, director and founder of the Scripps Research Translational Institute and executive vice president of Scripps Research. “In aggregating this information at the population level, sensor data provides a unique, real-time picture of how the virus is evolving across the nation.”

Using data gathered from March 25, 2020, to January 14, 2022, the study evaluated factors such as average resting heart rate and step count data across the 39,931 people who participated in the US. Scientists identified a person’s “anomalous” sensor days if they had a higher resting heart rate or lower step count when compared to their baseline data. They then compared these “anomalous” days against a model that predicted the CDC’s seven-day moving averages for COVID-19 cases in real-time, as well as six and 12 days in the future.

In tracking how physiological and behavioral changes may precede symptom onset and eventual testing, the scientists found that this sensor data significantly improved the seven-day average predictions by 32.9% in California—as well as by 12.2% in the United States for predictions occurring 12 days in the future.

The researchers were surprised at how well changes in sensor data tracked with changes in COVID-19 incidence, especially during huge peaks like the Omicron wave.

“All data streams—wastewater, electronic health records, pharmacy information and now sensor data—should be combined if we are to accurately forecast not only COVID-19 transmission, but also viral threats of the future,” says Jennifer Radin, PhD, MPH, an epidemiologist at the Scripps Research Translational Institute who is leading the study.

Radin notes that providing a real-time picture for what’s happening in the population is especially relevant now, as more people now test at home rather than in the clinic. And while wastewater surveillance has been a great resource for accomplishing this, the technology can be costly and isn’t available in most of the country.

“Nearly one in four people in the US have some sort of smartwatch, meaning that sensor data collection is an affordable, fast and convenient way to study viral onset in the broader population,” Radin adds.

The DETECT study is actively recruiting additional participants, and anyone in the United States with a smartphone who is 18 years or older can join. With enough people participating in the study, scientists can continue to improve their predictions on different viral threats and track how viruses like SARS-CoV-2 evolve through the population.

Learn more about DETECT at detectstudy.org.

In addition to Topol and Radin, the study, “Sensor-based surveillance for digitizing real-time COVID-19 tracking in the US: Developing and validating a multivariable population-based prediction model,” is authored by Giorgio Quer, Jay A. Pandit, Matteo Gadaleta, Katie Baca-Motes, Edward Ramos, Erin Coughlin, Katie Quartuccio and Steven R. Steinhubl of Scripps Research Translational Institute; Vik Kheterpal of CareEvolution; and Leo M. Wolansky of The Rockefeller Foundation.

The study was supported in part by the US National Institutes of Health/National Center for Advancing Translational Sciences grant UL1TR002550, The Rockefeller Foundation, and contribution of in-kind credits from Amazon Web Services via the Diagnostic Development Initiative.

About DETECT

Since its launch, the DETECT (Digital Engagement and Tracking for Early Control and Treatment) study has enrolled over 40,000 participants nationwide. The data that has been shared has enabled scientists to gain valuable insights into various aspects of COVID-19 infection. Already, DETECT has led to several peer-reviewed publications that: show how wearable devices are capable of detecting COVID-19 infection; give valuable insights into long COVID; demonstrate how machine learning techniques can predict COVID-19 infection; and more. The team aims to develop tools to complement traditional public health interventions and bolster the ability to prevent and contain future pandemics. The DETECT study is ongoing. Visit detect.scripps.edu to learn more.

About Scripps Research

Scripps Research is an independent, nonprofit biomedical institute ranked the most influential in the world for its impact on innovation by Nature Index. We are advancing human health through profound discoveries that address pressing medical concerns around the globe. Our drug discovery and development division, Calibr, works hand-in-hand with scientists across disciplines to bring new medicines to patients as quickly and efficiently as possible, while teams at Scripps Research Translational Institute harness genomics, digital medicine and cutting-edge informatics to understand individual health and render more effective healthcare. Scripps Research also trains the next generation of leading scientists at our Skaggs Graduate School, consistently named among the top 10 US programs for chemistry and biological sciences. Learn more at www.scripps.edu.

/Public Release. This material from the originating organization/author(s) may be of a point-in-time nature, edited for clarity, style and length. The views and opinions expressed are those of the author(s).View in full here.